CoChat
Sign Up
Cited by 222

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Dependence of Intracellular and Exosomal microRNAs on Viral E6/E7 Oncogene Expression in HPV-positive Tumor Cells

Honegger, Anja, Schilling, Daniela, Bastian, Sandra, Sponagel, Jasmin, Kuryshev, Vladimir, Sültmann, Holger, Scheffner, Martin, Hoppe-Seyler, Karin, Hoppe-Seyler, Felix·2015·PLOS Pathogens
DOI 10.1371/journal.ppat.1004712PMC PMC4356518
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1004712

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Silencing of HPV18 E6/E7 expression by RNA interference. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of HeLa cells with si18E6/E7, control siRNA siContr-1, or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 4). Asterisks above columns indicate statistically significant differences from siContr-1-treated cells (p ≤ 0.05 (*), p ≤ 0.001 (***)). (B) Immunoblot analysis of HPV18 E6, p53, and p21 protein levels, 72 h after transfection of HeLa cells with si18E6/E7 or siContr-1. α-Tubulin: loading control. (C) Immunoblot analysis of HPV18 E7, total pRb (pRb), phosphorylated pRb (pRb-P), and Cyclin A1 protein levels, 72 h after transfection of HeLa cells with si18E6/E7 or siContr-1. α-Tubulin: loading control.
Fig 1 Silencing of HPV18 E6/E7 expression by RNA interference. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of HeLa cells with si18E6/E7, control siRNA siContr-1, or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 4). Asterisks above columns indicate statistically significant differences from siContr-1-treated cells (p ≤ 0.05 (*), p ≤ 0.001 (***)). (B) Immunoblot analysis of HPV18 E6, p53, and p21 protein levels, 72 h after transfection of HeLa cells with si18E6/E7 or siContr-1. α-Tubulin: loading control. (C) Immunoblot analysis of HPV18 E7, total pRb (pRb), phosphorylated pRb (pRb-P), and Cyclin A1 protein levels, 72 h after transfection of HeLa cells with si18E6/E7 or siContr-1. α-Tubulin: loading control.CC BY · PubMed Central
Fig 2 Inhibition of endogenous HPV18 E6/E7 expression: Effects on the intracellular miRNA composition of cervical cancer cells. Small RNA deep sequencing (A—D) and qRT-PCR analyses (E) of cellular miRNAs, 72 h after transfection of HeLa cells with si18E6/E7 or control siRNA siContr-1. (A) Mean read count distribution of mature miRNA sequences in si18E6/E7- and siContr-1-transfected cells (n = 2). Only miRNAs with a mean read count > 1 were considered. (B) The 15 most frequently sequenced cellular miRNAs. Selection based on siContr-1 samples, respective values for the si18E6/E7-treatment are indicated. Data represent mean ± SEM (n = 2). Interrupted x-Axis. (C) Overview on differentially affected (> 1.5-fold) cellular miRNAs, determined by small RNA deep sequencing. RPM values of si18E6/E7-treated samples were calculated relative to the control treatment (siContr-1). Only miRNAs with > 1,000 RPM in each sample were considered (n = 2). (D) Relative quantification of miRNAs in si18E6/E7- versus siContr-1-treated cells as assessed by small RNA deep sequencing (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Only miRNAs with > 1,000 RPM in each sample were considered. Data represent mean ± SEM (n = 2). (E) qRT-PCR analyses of E6/E7-dependent cellular miRNAs identified by small RNA deep sequencing. Cellular miRNA levels were normalized to snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). The column color shows regulation in the same (dark grey) or opposite (light grey) direction compared to the small RNA deep sequencing data of the individual miRNAs. Data represent mean ± SEM (n = 2 or 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).
Fig 2 Inhibition of endogenous HPV18 E6/E7 expression: Effects on the intracellular miRNA composition of cervical cancer cells. Small RNA deep sequencing (A—D) and qRT-PCR analyses (E) of cellular miRNAs, 72 h after transfection of HeLa cells with si18E6/E7 or control siRNA siContr-1. (A) Mean read count distribution of mature miRNA sequences in si18E6/E7- and siContr-1-transfected cells (n = 2). Only miRNAs with a mean read count > 1 were considered. (B) The 15 most frequently sequenced cellular miRNAs. Selection based on siContr-1 samples, respective values for the si18E6/E7-treatment are indicated. Data represent mean ± SEM (n = 2). Interrupted x-Axis. (C) Overview on differentially affected (> 1.5-fold) cellular miRNAs, determined by small RNA deep sequencing. RPM values of si18E6/E7-treated samples were calculated relative to the control treatment (siContr-1). Only miRNAs with > 1,000 RPM in each sample were considered (n = 2). (D) Relative quantification of miRNAs in si18E6/E7- versus siContr-1-treated cells as assessed by small RNA deep sequencing (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Only miRNAs with > 1,000 RPM in each sample were considered. Data represent mean ± SEM (n = 2). (E) qRT-PCR analyses of E6/E7-dependent cellular miRNAs identified by small RNA deep sequencing. Cellular miRNA levels were normalized to snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). The column color shows regulation in the same (dark grey) or opposite (light grey) direction compared to the small RNA deep sequencing data of the individual miRNAs. Data represent mean ± SEM (n = 2 or 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).CC BY · PubMed Central
Fig 3 Inhibition of endogenous HPV16 E6/E7 expression: Effects on selected intracellular miRNAs. (A) Immunoblot analysis of HPV16 E7, HPV16 E6, p53 and p21 protein levels, 72 h after transfection of SiHa cells with si16E6/E7 or control siRNA (siContr-1), or upon mock treatment. α-Tubulin: loading control. (B) qRT-PCR analyses of ten selected cellular miRNAs, 72 h after transfection of SiHa cells with si16E6/E7 or siContr-1. Cellular miRNA levels were normalized to the snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*) and p ≤ 0.01 (**)).
Fig 3 Inhibition of endogenous HPV16 E6/E7 expression: Effects on selected intracellular miRNAs. (A) Immunoblot analysis of HPV16 E7, HPV16 E6, p53 and p21 protein levels, 72 h after transfection of SiHa cells with si16E6/E7 or control siRNA (siContr-1), or upon mock treatment. α-Tubulin: loading control. (B) qRT-PCR analyses of ten selected cellular miRNAs, 72 h after transfection of SiHa cells with si16E6/E7 or siContr-1. Cellular miRNA levels were normalized to the snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*) and p ≤ 0.01 (**)).CC BY · PubMed Central
Fig 4 Effects of the p53 status on the E6/E7-dependent modulation of intracellular miRNAs. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7, control siRNA (siContr-1), or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control (mock). Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from siContr-1-treated cells (p ≤ 0.05 (*), p ≤ 0.001 (***)). (B) Immunoblot analysis of HPV18 E6, p53 and p21 protein levels, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7 or siContr-1, or upon mock treatment. α-Tubulin: loading control. (C) qRT-PCR analyses of selected cellular miRNAs, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7 or siContr-1. miR-34a-3p, positive control miRNA (p53-inducible). Cellular miRNA levels were normalized to snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).
Fig 4 Effects of the p53 status on the E6/E7-dependent modulation of intracellular miRNAs. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7, control siRNA (siContr-1), or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control (mock). Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from siContr-1-treated cells (p ≤ 0.05 (*), p ≤ 0.001 (***)). (B) Immunoblot analysis of HPV18 E6, p53 and p21 protein levels, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7 or siContr-1, or upon mock treatment. α-Tubulin: loading control. (C) qRT-PCR analyses of selected cellular miRNAs, 72 h after transfection of parental or “p53-null” HeLa cells with si18E6/E7 or siContr-1. miR-34a-3p, positive control miRNA (p53-inducible). Cellular miRNA levels were normalized to snRNA RNU6–2 and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).CC BY · PubMed Central
Fig 5 Influence of combined silencing of p21 and HPV18 E6/E7 expression on the senescent phenotype of HPV-positive cancer cells. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of HeLa cells with the indicated siRNAs or in mock-treated cells. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 2 or 3). Asterisks above columns indicate statistically significant differences between the indicated treatments (p ≤ 0.05 (*), p ≤ 0.01 (**)). (B) Immunoblot analysis of HPV18 E7, p53, and p21 protein levels, 72 h after transfection of HeLa cells with the indicated siRNAs or upon mock-treatment. α-Tubulin: loading control. (C + D) Cell cycle distribution analyzed by FACS, 72 h after transfection of HeLa cells with the indicated siRNAs or upon mock treatment. Percentage of cells in the G1, S and G2 cell cycle phases are indicated. Representative samples of one experiment are shown as well as a summary of multiple biological replicates. Data represent mean ± SEM (n = 3). (E) HeLa cells were stained for expression of the senescence marker SA-β-Gal, 168 h after transfection with the indicated siRNAs. Visualization by bright field microscopy.
Fig 5 Influence of combined silencing of p21 and HPV18 E6/E7 expression on the senescent phenotype of HPV-positive cancer cells. (A) qRT-PCR analysis of HPV18 E6/E7 (left panel) and p21 (right panel) mRNA expression, 72 h after transfection of HeLa cells with the indicated siRNAs or in mock-treated cells. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 2 or 3). Asterisks above columns indicate statistically significant differences between the indicated treatments (p ≤ 0.05 (*), p ≤ 0.01 (**)). (B) Immunoblot analysis of HPV18 E7, p53, and p21 protein levels, 72 h after transfection of HeLa cells with the indicated siRNAs or upon mock-treatment. α-Tubulin: loading control. (C + D) Cell cycle distribution analyzed by FACS, 72 h after transfection of HeLa cells with the indicated siRNAs or upon mock treatment. Percentage of cells in the G1, S and G2 cell cycle phases are indicated. Representative samples of one experiment are shown as well as a summary of multiple biological replicates. Data represent mean ± SEM (n = 3). (E) HeLa cells were stained for expression of the senescence marker SA-β-Gal, 168 h after transfection with the indicated siRNAs. Visualization by bright field microscopy.CC BY · PubMed Central
Fig 6 Effects of miRNAs of the miR-17~92 cluster on p21 expression in HeLa cells. (A) qRT-PCR analyses of cellular miRNA levels, 72 h after transfection of HeLa cells with the indicated vectors or upon mock treatment. miR-17~92: vector coding for the mir-17~92 cluster; “control”: repective empty expression vector. miRNA levels were normalized to snRNA RNU6–2 and calculated relative to the mock control. miR-17–5p, miR-20a-5p, miR-19b-3p, miR-92a-3p: encoded by the mir-17~92 expression vector; miR-34a-5p: negative control (not encoded by the vector). Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from vector control-treated cells (p ≤ 0.05 (*)). (B) qRT-PCR analysis of p21 mRNA expression, 72 h after transfection of HeLa cells with the indicated vectors or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 4). Asterisks above columns indicate statistically significant differences from vector control-treated cells (p ≤ 0.05 (*)). (C) Immunoblot analysis of p53 and p21 protein levels, 72 h after transfection with the indicated vectors. α-Tubulin: loading control. A representative image is shown with corresponding densitometrically quantified band intensities of p21, normalized to α-Tubulin and calculated relative to mock. (D) miRNA inhibitors against miR-17–5p and miR-20a-5p increase the expression of p21 in HeLa cells. Left panel: Immunoblot analysis of p53 and p21 protein levels, 72 h after transfection of HeLa cells with the indicated miRNA inhibitors, an inhibitor control (‘Inhib. control’), or upon mock treatment. α-Tubulin: loading control. A representative image is shown. Numbers below individual lanes correspond to densitometrically quantified band intensities for p21, normalized to α-Tubulin and calculated relative to the Inhib. control. Right panel: Summary of densitometric quantification of p21 protein signal intensities. Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from Inhib. control-treated cells (p ≤ 0.05 (*), p ≤ 0.01 (**)).
Fig 6 Effects of miRNAs of the miR-17~92 cluster on p21 expression in HeLa cells. (A) qRT-PCR analyses of cellular miRNA levels, 72 h after transfection of HeLa cells with the indicated vectors or upon mock treatment. miR-17~92: vector coding for the mir-17~92 cluster; “control”: repective empty expression vector. miRNA levels were normalized to snRNA RNU6–2 and calculated relative to the mock control. miR-17–5p, miR-20a-5p, miR-19b-3p, miR-92a-3p: encoded by the mir-17~92 expression vector; miR-34a-5p: negative control (not encoded by the vector). Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from vector control-treated cells (p ≤ 0.05 (*)). (B) qRT-PCR analysis of p21 mRNA expression, 72 h after transfection of HeLa cells with the indicated vectors or upon mock treatment. mRNA levels were normalized to ACTB and calculated relative to the mock control. Data represent mean ± SEM (n = 4). Asterisks above columns indicate statistically significant differences from vector control-treated cells (p ≤ 0.05 (*)). (C) Immunoblot analysis of p53 and p21 protein levels, 72 h after transfection with the indicated vectors. α-Tubulin: loading control. A representative image is shown with corresponding densitometrically quantified band intensities of p21, normalized to α-Tubulin and calculated relative to mock. (D) miRNA inhibitors against miR-17–5p and miR-20a-5p increase the expression of p21 in HeLa cells. Left panel: Immunoblot analysis of p53 and p21 protein levels, 72 h after transfection of HeLa cells with the indicated miRNA inhibitors, an inhibitor control (‘Inhib. control’), or upon mock treatment. α-Tubulin: loading control. A representative image is shown. Numbers below individual lanes correspond to densitometrically quantified band intensities for p21, normalized to α-Tubulin and calculated relative to the Inhib. control. Right panel: Summary of densitometric quantification of p21 protein signal intensities. Data represent mean ± SEM (n = 3). Asterisks above columns indicate statistically significant differences from Inhib. control-treated cells (p ≤ 0.05 (*), p ≤ 0.01 (**)).CC BY · PubMed Central
Fig 7 Characterization of exosomes secreted by HeLa cells used for small RNA deep sequencing. (A) Immunoblot analysis of total cellular extract (30, 10 and 1 μg) from exosome-producing cells, and of 1 μg protein from exosome preparations. Hsc70, CD63, Annexin-1, CD9 and β-Actin: exosomal markers; EEA1: early endosome marker; GRP78: ER marker. (B) Visualization of exosomes by electron microscopy. Bar corresponds to 100 nm. (C) Characterization of cellular and exosomal RNA. Electropherograms of total RNA isolated from HeLa cells and from RNAse A-treated exosomes. Upper panel: total RNA contents; lower panel: small RNA contents. M = marker. Shown are representative images for siContr-1-treated samples.
Fig 7 Characterization of exosomes secreted by HeLa cells used for small RNA deep sequencing. (A) Immunoblot analysis of total cellular extract (30, 10 and 1 μg) from exosome-producing cells, and of 1 μg protein from exosome preparations. Hsc70, CD63, Annexin-1, CD9 and β-Actin: exosomal markers; EEA1: early endosome marker; GRP78: ER marker. (B) Visualization of exosomes by electron microscopy. Bar corresponds to 100 nm. (C) Characterization of cellular and exosomal RNA. Electropherograms of total RNA isolated from HeLa cells and from RNAse A-treated exosomes. Upper panel: total RNA contents; lower panel: small RNA contents. M = marker. Shown are representative images for siContr-1-treated samples.CC BY · PubMed Central
Fig 8 Inhibition of endogenous HPV18 E6/E7 expression: Effects on the miRNA composition of exosomes secreted by cervical cancer cells. Small RNA deep sequencing (A—D) and qRT-PCR analyses (E) of exosomal miRNAs, 72 h after transfection of HeLa cells with si18E6/E7 or control siRNA (siContr-1), and subsequent exosome purification from the cell culture supernatant. (A) Mean read count distribution of mature miRNA sequences in exosomes released from si18E6/E7- and siContr-1-treated HeLa cells (n = 3). Only miRNAs with a mean read count > 1 were considered. (B) The 15 most frequently sequenced exosomal miRNAs. Selection based on siContr-1 samples, respective values for si18E6/E7-treatment are indicated. Data represent mean ± SEM (n = 3). Interrupted x-Axis. (C) Overview on differentially deregulated (> 1.5-fold) exosomal miRNAs determined by small RNA deep sequencing. RPM values of si18E6/E7-treated samples were calculated relative to the control treatment (siContr-1). Only miRNAs with > 1,000 RPM in each sample were considered (n = 2). (D) Relative quantification of miRNAs in exosomes released from si18E6/E7- versus siContr-1-treated cells, as assessed by small RNA deep sequencing (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Only miRNAs with > 1,000 RPM in each sample were considered. Data represent mean ± SEM (n = 3). (E) qRT-PCR analysis of E6/E7-dependent exosomal miRNAs identified by small RNA deep sequencing. Exosomal miRNA levels were normalized to miR-452–5p and miR-183–5p and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). The column color shows regulation in the same (dark grey) or opposite (light grey) direction compared to the small RNA deep sequencing data of the individual miRNAs. Ct-values > 35 were considered as not detected (n.d.). Data represent mean ± SEM (n = 2 or 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**)).
Fig 8 Inhibition of endogenous HPV18 E6/E7 expression: Effects on the miRNA composition of exosomes secreted by cervical cancer cells. Small RNA deep sequencing (A—D) and qRT-PCR analyses (E) of exosomal miRNAs, 72 h after transfection of HeLa cells with si18E6/E7 or control siRNA (siContr-1), and subsequent exosome purification from the cell culture supernatant. (A) Mean read count distribution of mature miRNA sequences in exosomes released from si18E6/E7- and siContr-1-treated HeLa cells (n = 3). Only miRNAs with a mean read count > 1 were considered. (B) The 15 most frequently sequenced exosomal miRNAs. Selection based on siContr-1 samples, respective values for si18E6/E7-treatment are indicated. Data represent mean ± SEM (n = 3). Interrupted x-Axis. (C) Overview on differentially deregulated (> 1.5-fold) exosomal miRNAs determined by small RNA deep sequencing. RPM values of si18E6/E7-treated samples were calculated relative to the control treatment (siContr-1). Only miRNAs with > 1,000 RPM in each sample were considered (n = 2). (D) Relative quantification of miRNAs in exosomes released from si18E6/E7- versus siContr-1-treated cells, as assessed by small RNA deep sequencing (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Only miRNAs with > 1,000 RPM in each sample were considered. Data represent mean ± SEM (n = 3). (E) qRT-PCR analysis of E6/E7-dependent exosomal miRNAs identified by small RNA deep sequencing. Exosomal miRNA levels were normalized to miR-452–5p and miR-183–5p and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). The column color shows regulation in the same (dark grey) or opposite (light grey) direction compared to the small RNA deep sequencing data of the individual miRNAs. Ct-values > 35 were considered as not detected (n.d.). Data represent mean ± SEM (n = 2 or 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**)).CC BY · PubMed Central
Fig 9 Inhibition of endogenous HPV16 E6/E7 expression: Effects on selected exosomal miRNAs. qRT-PCR analysis of selected exosomal miRNAs, 72 h after transfection of SiHa cells with si16E6/E7 or control siRNA (siContr-1), and subsequent exosome purification from the cell culture supernatant. Exosomal miRNA levels were normalized to miR-452–5p and miR-183–5p and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).
Fig 9 Inhibition of endogenous HPV16 E6/E7 expression: Effects on selected exosomal miRNAs. qRT-PCR analysis of selected exosomal miRNAs, 72 h after transfection of SiHa cells with si16E6/E7 or control siRNA (siContr-1), and subsequent exosome purification from the cell culture supernatant. Exosomal miRNA levels were normalized to miR-452–5p and miR-183–5p and calculated relative to siContr-1 (log2 display). Dashed lines: 1.5-fold up- or downregulation (log2(1.5) = 0.585). Data represent mean ± SEM (n = 3). Asterisks indicate statistically significant differences (p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***)).CC BY · PubMed Central
Fig 10 HPV oncogenes control p21 expression at multiple levels. E6 can repress p21 transcription at the promoter level by inducing the degradation of the p21 transcriptional activator p53; sustained E6/E7 expression maintains the concentration of miR-17 family members in HPV-positive cancer cells which repress p21 expression by targeting the p21 mRNA; the E7 protein can directly bind to the p21 protein and inhibit its function.
Fig 10 HPV oncogenes control p21 expression at multiple levels. E6 can repress p21 transcription at the promoter level by inducing the degradation of the p21 transcriptional activator p53; sustained E6/E7 expression maintains the concentration of miR-17 family members in HPV-positive cancer cells which repress p21 expression by targeting the p21 mRNA; the E7 protein can directly bind to the p21 protein and inhibit its function.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 127

  1. H zur Hausen, 2002, Papillomaviruses and cancer: from basic studies to clinical application, Nat Rev Cancer, 2, 342, 10.1038/nrc798 · DOI
  2. M von Knebel Doeberitz, 1988, Correlation of modified human papilloma virus early gene expression with altered growth properties in C4–1 cervical carcinoma cells, Cancer Res, 48, 3780
  3. ME McLaughlin-Drubin, 2009, Oncogenic activities of human papillomaviruses, Virus Res, 143, 195, 10.1016/j.virusres.2009.06.008 · DOI
  4. M Scheffner, 1990, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 · DOI · Paper page
  5. AJ Klingelhutz, 1996, Telomerase activation by the E6 gene product of human papillomavirus type 16, Nature, 380, 79, 10.1038/380079a0 · DOI
  6. ME McLaughlin-Drubin, 2009, The human papillomavirus E7 oncoprotein, Virology, 384, 335, 10.1016/j.virol.2008.10.006 · DOI
  7. K Butz, 2000, Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein, Proc Natl Acad Sci U S A, 97, 6693, 10.1073/pnas.110538897 · DOI
  8. K Butz, 2003, siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells, Oncogene, 22, 5938, 10.1038/sj.onc.1206894 · DOI
  9. H Griffin, 2006, Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting, J Mol Biol, 355, 360, 10.1016/j.jmb.2005.10.077 · DOI
  10. K Yamato, 2008, New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer, Cancer Gene Ther, 15, 140, 10.1038/sj.cgt.7701118 · DOI
  11. M Lagrange, 2007, Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells, Biochem Biophys Res Commun, 361, 487, 10.1016/j.bbrc.2007.07.040 · DOI
  12. EC Goodwin, 2000, Rapid induction of senescence in human cervical carcinoma cells, Proc Natl Acad Sci U S A, 97, 10978, 10.1073/pnas.97.20.10978 · DOI
  13. SI Wells, 2000, Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways, EMBO J, 19, 5762, 10.1093/emboj/19.21.5762 · DOI
  14. AH Hall, 2003, RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells, J Virol, 77, 6066, 10.1128/JVI.77.10.6066-6069.2003 · DOI
  15. MS Ebert, 2012, Roles for microRNAs in conferring robustness to biological processes, Cell, 149, 515, 10.1016/j.cell.2012.04.005 · DOI · Paper page
  16. JB Cowland, 2007, MicroRNAs and cancer, APMIS, 115, 1090, 10.1111/j.1600-0463.2007.apm_775.xml.x · DOI
  17. MV Iorio, 2012, MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review, EMBO Mol Med, 4, 143, 10.1002/emmm.201100209 · DOI
  18. V Olive, 2013, mir-17–92: a polycistronic oncomir with pleiotropic functions, Immunol Rev, 253, 158, 10.1111/imr.12054 · DOI
  19. T Kuilman, 2010, The essence of senescence, Genes Dev, 24, 2463, 10.1101/gad.1971610 · DOI · Paper page
  20. RP Kincaid, 2012, Virus-encoded microRNAs: an overview and a look to the future, PLoS Pathog, 8, e1003018, 10.1371/journal.ppat.1003018 · DOI
  21. X Wang, 2014, microRNAs are biomarkers of oncogenic human papillomavirus infections, Proc Natl Acad Sci U S A, 111, 4262, 10.1073/pnas.1401430111 · DOI
  22. V Villegas-Ruiz, 2014, Heterogeneity of microRNAs expression in cervical cancer cells: over-expression of miR-196a, Int J Clin Exp Pathol, 7, 1389
  23. C Lin, 2014, Roles of MiR-101 and its target gene Cox-2 in early diagnosis of cervical cancer in Uygur women, Asian Pac J Cancer Prev, 15, 45, 10.7314/APJCP.2014.15.1.45 · DOI
  24. D Ma, 2012, Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer, Chin Med J (Engl), 125, 4270
  25. TH Cheung, 2012, Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm, Cell Cycle, 11, 2876, 10.4161/cc.21278 · DOI
  26. CB Lajer, 2012, The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer, Br J Cancer, 106, 1526, 10.1038/bjc.2012.109 · DOI
  27. SM Wilting, 2013, Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis, Oncogene, 32, 106, 10.1038/onc.2012.20 · DOI
  28. L Liu, 2012, miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2, Mol Med Rep, 5, 753
  29. Y Li, 2011, Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29, J Pathol, 224, 484, 10.1002/path.2873 · DOI
  30. Q Rao, 2012, Aberrant microRNA expression in human cervical carcinomas, Med Oncol, 29, 1242, 10.1007/s12032-011-9830-2 · DOI
  31. JH Li, 2011, MicroRNA miR-886–5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells, Gynecol Oncol, 120, 145, 10.1016/j.ygyno.2010.09.009 · DOI
  32. PM Pereira, 2010, MicroRNA expression variability in human cervical tissues, PLoS One, 5, e11780, 10.1371/journal.pone.0011780 · DOI
  33. X Wang, 2008, Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth, PLoS One, 3, e2557, 10.1371/journal.pone.0002557 · DOI
  34. JW Lee, 2008, Altered MicroRNA expression in cervical carcinomas, Clin Cancer Res, 14, 2535, 10.1158/1078-0432.CCR-07-1231 · DOI
  35. D Witten, 2010, Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls, BMC Biol, 8, 58, 10.1186/1741-7007-8-58 · DOI
  36. H Park, 2014, Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: Clinical impact of miR-363–3p, Gynecol Oncol, 135, 565, 10.1016/j.ygyno.2014.09.010 · DOI
  37. S Liang, 2014, Microarray analysis revealed markedly differential miRNA expression profiles in cervical intraepithelial neoplasias and invasive squamous cell carcinoma, Future Oncol, 10, 2023, 10.2217/fon.14.38 · DOI
  38. T Tang, 2013, MicroRNA-182 plays an onco-miRNA role in cervical cancer, Gynecol Oncol, 129, 199, 10.1016/j.ygyno.2012.12.043 · DOI
  39. WO Lui, 2007, Patterns of known and novel small RNAs in human cervical cancer, Cancer Res, 67, 6031, 10.1158/0008-5472.CAN-06-0561 · DOI
  40. I Martinez, 2008, Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells, Oncogene, 27, 2575, 10.1038/sj.onc.1210919 · DOI
  41. A Dreher, 2011, Differential expression of cellular microRNAs in HPV 11, -16, and-45 transfected cells, Biochem Biophys Res Commun, 412, 20, 10.1016/j.bbrc.2011.07.011 · DOI
  42. V Gunasekharan, 2013, Human papillomaviruses modulate microRNA 145 expression to directly control genome amplification, J Virol, 87, 6037, 10.1128/JVI.00153-13 · DOI
  43. S Yablonska, 2013, Identification of miRNAs Dysregulated in Human Foreskin Keratinocytes (HFKs) Expressing the Human Papillomavirus (HPV) Type 16 E6 and E7 Oncoproteins, Microrna, 2, 2, 10.2174/2211536611302010002 · DOI
  44. X Wang, 2009, Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6, RNA, 15, 637, 10.1261/rna.1442309 · DOI
  45. DJ McKenna, 2010, MicroRNA 203 expression in keratinocytes is dependent on regulation of p53 levels by E6, J Virol, 84, 10644, 10.1128/JVI.00703-10 · DOI
  46. J Kowal, 2014, Biogenesis and secretion of exosomes, Curr Opin Cell Biol, 29C, 116, 10.1016/j.ceb.2014.05.004 · DOI · Paper page
  47. J Rak, 2013, Extracellular vesicles—biomarkers and effectors of the cellular interactome in cancer, Front Pharmacol, 4, 21
  48. VR Martins, 2013, Tumor-cell-derived microvesicles as carriers of molecular information in cancer, Curr Opin Oncol, 25, 66, 10.1097/CCO.0b013e32835b7c81 · DOI
  49. DM Pegtel, 2010, Functional delivery of viral miRNAs via exosomes, Proc Natl Acad Sci U S A, 107, 6328, 10.1073/pnas.0914843107 · DOI
  50. T Kogure, 2011, Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth, Hepatology, 54, 1237, 10.1002/hep.24504 · DOI · Paper page
  51. A Montecalvo, 2012, Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes, Blood, 119, 756, 10.1182/blood-2011-02-338004 · DOI · Paper page
  52. S Rana, 2013, Exosomal tumor microRNA modulates premetastatic organ cells, Neoplasia, 15, 281, 10.1593/neo.122010 · DOI
  53. T Umezu, 2013, Leukemia cell to endothelial cell communication via exosomal miRNAs, Oncogene, 32, 2747, 10.1038/onc.2012.295 · DOI
  54. DG Meckes Jr., 2010, Human tumor virus utilizes exosomes for intercellular communication, Proc Natl Acad Sci U S A, 107, 20370, 10.1073/pnas.1014194107 · DOI
  55. DM Pegtel, 2011, Viral miRNAs exploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion, Biochim Biophys Acta, 1809, 715, 10.1016/j.bbagrm.2011.08.002 · DOI
  56. PE Chugh, 2013, Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies, PLoS Pathog, 9, e1003484, 10.1371/journal.ppat.1003484 · DOI
  57. C D’Souza-Schorey, 2012, Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers, Genes Dev, 26, 1287, 10.1101/gad.192351.112 · DOI
  58. F Properzi, 2013, Exosomes: the future of biomarkers in medicine, Biomark Med, 7, 769, 10.2217/bmm.13.63 · DOI
  59. DD Taylor, 2013, The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids, Front Genet, 4, 142, 10.3389/fgene.2013.00142 · DOI
  60. WS el-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
  61. G Mullokandov, 2012, High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries, Nat Methods, 9, 840, 10.1038/nmeth.2078 · DOI · Paper page
  62. A Hengstermann, 2005, Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53, J Virol, 79, 9296, 10.1128/JVI.79.14.9296-9300.2005 · DOI
  63. L Fontana, 2008, Antagomir-17–5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM, PLoS One, 3, e2236, 10.1371/journal.pone.0002236 · DOI
  64. S Wu, 2010, Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region, Oncogene, 29, 2302, 10.1038/onc.2010.34 · DOI · Paper page
  65. RA DeFilippis, 2003, Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells, J Virol, 77, 1551, 10.1128/JVI.77.2.1551-1563.2003 · DOI
  66. DD Taylor, 2008, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecol Oncol, 110, 13, 10.1016/j.ygyno.2008.04.033 · DOI
  67. SA Bellingham, 2012, Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells, Nucleic Acids Res
  68. L Moldovan, 2013, Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR, Methods Mol Biol, 1024, 129, 10.1007/978-1-62703-453-1_10 · DOI
  69. EC Goodwin, 2000, Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways, Proc Natl Acad Sci U S A, 97, 12513, 10.1073/pnas.97.23.12513 · DOI
  70. TG Magaldi, 2012, Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation, Virology, 422, 114, 10.1016/j.virol.2011.10.012 · DOI
  71. ES Hwang, 1993, Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene, J Virol, 67, 3720, 10.1128/JVI.67.7.3720-3729.1993 · DOI
  72. JJ Dowhanick, 1995, Suppression of cellular proliferation by the papillomavirus E2 protein, J Virol, 69, 7791, 10.1128/JVI.69.12.7791-7799.1995 · DOI
  73. A Honegger, 2013, Silencing of human papillomavirus (HPV) E6/E7 oncogene expression affects both the contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells, Int J Cancer
  74. M Durst, 1989, Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene, Virology, 173, 767, 10.1016/0042-6822(89)90595-3 · DOI
  75. R Kuner, 2007, Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses, J Mol Med (Berl), 85, 1253, 10.1007/s00109-007-0230-1 · DOI
  76. A Buitrago-Perez, 2009, Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling, Curr Genomics, 10, 26, 10.2174/138920209787581235 · DOI
  77. HI Suzuki, 2009, Modulation of microRNA processing by p53, Nature, 460, 529, 10.1038/nature08199 · DOI
  78. H Ding, 2014, Characterization of the microRNA expression profile of cervical squamous cell carcinoma metastases, Asian Pac J Cancer Prev, 15, 1675, 10.7314/APJCP.2014.15.4.1675 · DOI
  79. YT Chou, 2010, EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF, Cancer Res, 70, 8822, 10.1158/0008-5472.CAN-10-0638 · DOI
  80. JA Foekens, 2008, Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer, Proc Natl Acad Sci U S A, 105, 13021, 10.1073/pnas.0803304105 · DOI
  81. M Hatziapostolou, 2011, An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis, Cell, 147, 1233, 10.1016/j.cell.2011.10.043 · DOI
  82. L Yang, 2012, A functional polymorphism at microRNA-629-binding site in the 3′-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population, Carcinogenesis, 33, 338, 10.1093/carcin/bgr272 · DOI
  83. JM Dhahbi, 2011, Deep sequencing reveals novel microRNAs and regulation of microRNA expression during cell senescence, PLoS One, 6, e20509, 10.1371/journal.pone.0020509 · DOI
  84. DY Lee, 2007, MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression, Proc Natl Acad Sci U S A, 104, 20350, 10.1073/pnas.0706901104 · DOI
  85. DD Jima, 2010, Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs, Blood, 116, e118, 10.1182/blood-2010-05-285403 · DOI
  86. Y Zhang, 2011, FoxO family members in cancer, Cancer Biol Ther, 12, 253, 10.4161/cbt.12.4.15954 · DOI
  87. DE Kloet, 2011, The PKB/FOXO switch in aging and cancer, Biochim Biophys Acta, 1813, 1926, 10.1016/j.bbamcr.2011.04.003 · DOI
  88. R Chhabra, 2010, Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24–2 cluster and its implication in human diseases, Mol Cancer, 9, 232, 10.1186/1476-4598-9-232 · DOI
  89. H Dellago, 2013, High levels of oncomiR-21 contribute to the senescence-induced growth arrest in normal human cells and its knock-down increases the replicative lifespan, Aging Cell, 12, 446, 10.1111/acel.12069 · DOI
  90. S Lee, 2011, Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging, Cell Mol Life Sci, 68, 325, 10.1007/s00018-010-0457-9 · DOI
  91. Y Goto, 2014, The microRNA-23b/27b/24–1 cluster is a disease progression marker and tumor suppressor in prostate cancer, Oncotarget
  92. S Majid, 2012, miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer, Cancer Res, 72, 6435, 10.1158/0008-5472.CAN-12-2181 · DOI
  93. LN Bonifacio, 2010, MiRNA profile associated with replicative senescence, extended cell culture, and ectopic telomerase expression in human foreskin fibroblasts, PLoS One, 5, 10.1371/journal.pone.0012519 · DOI
  94. S Jiang, 2012, A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells, EMBO J, 31, 1985, 10.1038/emboj.2012.45 · DOI
  95. EA White, 2014, Genus Beta Human Papillomavirus E6 Proteins Vary in Their Effects on the Transactivation of p53 Target Genes, J Virol, 88, 8201, 10.1128/JVI.01197-14 · DOI
  96. JO Funk, 1997, Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein, Genes Dev, 11, 2090, 10.1101/gad.11.16.2090 · DOI
  97. DL Jones, 1997, The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2, Genes Dev, 11, 2101, 10.1101/gad.11.16.2101 · DOI
  98. J Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  99. N Yanaihara, 2006, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025 · DOI · Paper page
  100. C Villarroya-Beltri, 2013, Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs, Nat Commun, 4, 2980, 10.1038/ncomms3980 · DOI · Paper page
  101. B Boyerinas, 2010, The role of let-7 in cell differentiation and cancer, Endocr Relat Cancer, 17, F19, 10.1677/ERC-09-0184 · DOI
  102. GJ Nuovo, 2012, Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples, Mod Pathol, 25, 1333, 10.1038/modpathol.2012.95 · DOI
  103. S Volinia, 2012, Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA, Proc Natl Acad Sci U S A, 109, 3024, 10.1073/pnas.1200010109 · DOI
  104. L Hong, 2010, The miR-17–92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence, Cancer Res, 70, 8547, 10.1158/0008-5472.CAN-10-1938 · DOI
  105. M Li, 2014, miR-92a family and their target genes in tumorigenesis and metastasis, Exp Cell Res
  106. G Di Leva, 2014, MicroRNAs in cancer, Annu Rev Pathol, 9, 287, 10.1146/annurev-pathol-012513-104715 · DOI
  107. A Bobrie, 2011, Exosome secretion: molecular mechanisms and roles in immune responses, Traffic, 12, 1659, 10.1111/j.1600-0854.2011.01225.x · DOI
  108. A Turchinovich, 2011, Characterization of extracellular circulating microRNA, Nucleic Acids Res, 39, 7223, 10.1093/nar/gkr254 · DOI · Paper page
  109. Z Williams, 2013, Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations, Proc Natl Acad Sci U S A, 110, 4255, 10.1073/pnas.1214046110 · DOI
  110. N Nouraee, 2013, MicroRNAs as Cancer Biomarkers, Microrna, 2, 102, 10.2174/22115366113029990015 · DOI
  111. A Gallo, 2012, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, PLoS One, 7, e30679, 10.1371/journal.pone.0030679 · DOI · Paper page
  112. SP Nana-Sinkam, 2013, Clinical applications for microRNAs in cancer, Clin Pharmacol Ther, 93, 98, 10.1038/clpt.2012.192 · DOI
  113. BD Parsons, 2009, A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay, PLoS One, 4, e8471, 10.1371/journal.pone.0008471 · DOI
  114. AL Jackson, 2010, Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application, Nat Rev Drug Discov, 9, 57, 10.1038/nrd3010 · DOI
  115. C Chen, 1987, High-efficiency transformation of mammalian cells by plasmid DNA, Mol Cell Biol, 7, 2745, 10.1128/MCB.7.8.2745 · DOI
  116. KA O’Donnell, 2005, c-Myc-regulated microRNAs modulate E2F1 expression, Nature, 435, 839, 10.1038/nature03677 · DOI · Paper page
  117. MH Fox, 1980, A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry, Cytometry, 1, 71, 10.1002/cyto.990010114 · DOI
  118. GP Dimri, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc Natl Acad Sci U S A, 92, 9363, 10.1073/pnas.92.20.9363 · DOI · Paper page
  119. K Butz, 1998, Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress, Oncogene, 17, 781, 10.1038/sj.onc.1201995 · DOI
  120. I Crnkovic-Mertens, 2006, Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells, J Mol Med (Berl), 84, 232, 10.1007/s00109-005-0021-5 · DOI
  121. KJ Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25, 402, 10.1006/meth.2001.1262 · DOI · Paper page
  122. MR Friedlander, 2012, miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades, Nucleic Acids Res, 40, 37, 10.1093/nar/gkr688 · DOI · Paper page
  123. J Weischenfeldt, 2013, Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer, Cancer Cell, 23, 159, 10.1016/j.ccr.2013.01.002 · DOI
  124. S Griffiths-Jones, 2004, The microRNA Registry, Nucleic Acids Res, 32, D109, 10.1093/nar/gkh023 · DOI
  125. S Griffiths-Jones, 2006, miRBase: microRNA sequences, targets and gene nomenclature, Nucleic Acids Res, 34, D140, 10.1093/nar/gkj112 · DOI · Paper page
  126. S Griffiths-Jones, 2008, miRBase: tools for microRNA genomics, Nucleic Acids Res, 36, D154, 10.1093/nar/gkm952 · DOI
  127. A Kozomara, 2011, miRBase: integrating microRNA annotation and deep-sequencing data, Nucleic Acids Res, 39, D152, 10.1093/nar/gkq1027 · DOI · Paper page

Cited by

Sorted by citations

See all 222

Metadata

Authors
Honegger, A., Schilling, D., Bastian, S., Sponagel, J., Kuryshev, V., Sültmann, H., Scheffner, M., Hoppe-Seyler, K., & Hoppe-Seyler, F.
Venue
PLOS Pathogens
Publisher
Public Library of Science (PLoS)
Published
2015-03-11
Volume
11
Issue
3
Pages
e1004712
ISSN
1553-7374
DOI
10.1371/journal.ppat.1004712
PMC
PMC4356518
Cited by
222
References
7
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review